AstraZeneca reports that its second-quarter profit increases as strong sales of its cancer medicines lift overall performance. Multiple outlets say profit after tax rises about 2% in the three months ended June 30, reaching roughly US$2.5 billion versus the same period a year earlier. One report also highlights that core earnings per share increase to US$2.63 in the quarter, exceeding analyst expectations cited by the outlet of US$2.48.
Euronews and Quartz both state that the stronger results help the company sustain its guidance. AstraZeneca maintains its 2026 outlook, according to Euronews, while Quartz says the company also keeps its full-year and longer-term (2030) outlooks despite the quarter’s beat. Seeking Alpha similarly frames the quarter as an earnings performance that comes in above estimates, driven by continued momentum in cancer drug sales.
Overall, the coverage converges on the same picture: higher profit and an earnings beat, underpinned by cancer drug revenue strength and accompanied by maintained company outlooks.
